Biotech Trailblazer With A 26.53% Upside Potential
Maze Therapeutics, Inc. (NASDAQ: MAZE) emerges as a compelling player in the biotechnology sector, boasting a market capitalization of $1.44 billion. Operating out of South San Francisco, California, Maze is a clinical-stage biopharmaceutical firm focused on developing small molecule precision medicines targeting renal, cardiovascular, metabolic diseases, and obesity. With a current stock price of $29.90, Maze offers investors a potential upside of 26.53% based on an average target price of $37.83, as forecasted by analysts.
Maze’s innovation pipeline is led by MZE829, an oral small molecule inhibitor of apolipoprotein L1 (APOL1), which is currently in phase II clinical trials for APOL1 kidney disease. The company’s commitment…
